The Multipurpose Arthritis and Musculoskeletal Diseases Center (MAMDC) of the University of Alabama at Birmingham (UAB) is a multidisciplinary effort, involving faculty and staff of the Schools of Medicine, Dentistry, Nursing, Public Health, and Health Related Professions, and the University Hospital. A broad spectrum of biomedical, epidemiologic, education, and health services-based research efforts is focused on substantive problems posed by the rheumatic and musculoskeletal diseases. Biomedical research in the UAB MAMDC includes studies in the areas of immunology, virology, molecular biology, immunogenetics, connective tissue biochemistry, and clinical rheumatology. This application includes five new biomedical research feasibility proposals addressing basic processes relevant to the pathogenesis of the rheumatic and musculoskeletal diseases. Three Research Core Units are also proposed: continuation of the highly successful Hybridoma and Flow Cytometry Core Facilities and initiation of the MAMDC Gene Targeting Core Facility. Three projects are proposed which address fundamental epidemiology, education and health services problems related to the rheumatic diseases. Proposed efforts include projects directed toward: 1) investigating the impact of telephone counseling on outcomes and economic impact of disease in patients with SLE; 2) investigating approaches to improving outcomes of vocational rehabilitation in patients with musculoskeletal diseases; and 3) elucidating mechanisms underlying pain in fibromyalgia. The overall goals of the MAMDC are to coordinate existing arthritis and musculoskeletal disease research programs and initiate new ones so that we can achieve: (1) greater knowledge of the etiologies and pathogenetic mechanisms underlying rheumatic and musculoskeletal diseases; (2) improved therapies for these diseases; (3) better methods of health education; (4) elucidation of epidemiologic aspects of arthritis and related conditions; (5) improvement of patient services; and (6) a more enlightened community attitude towards arthritis and the musculoskeletal diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR020614-24
Application #
6341764
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Freeman, Julia B
Project Start
1977-09-20
Project End
2002-12-31
Budget Start
2001-01-01
Budget End
2002-12-31
Support Year
24
Fiscal Year
2001
Total Cost
$1,104,617
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5:1585-92
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14

Showing the most recent 10 out of 145 publications